A 26-week open-label study of quetiapine in children with conduct disorder

Robert L Findling, Michael D. Reed, Mary Ann O'Riordan, Christine A. Demeter, Robert J. Stansbrey, Nora K. McNamara

Research output: Contribution to journalArticle

Abstract

Objective: The aim of this study was to describe the long-term safety and effectiveness of quetiapine in conduct disorder (CD). Methods: This was an 13-week outpatient follow-up study of an acute trial that enrolled aggressive children ages 6-12 years with a primary diagnosis of CD. To be enrolled into this study, subjects had to have successfully completed participation in the initial 3-week, open-label, outpatient quetiapine trial. Psychometric measures included the Rating of Aggression Against People and/or Property Scale (RAAPP), the Nisonger Child Behavior Rating Form (NCBRF), the Conners' Parent Rating Scale (CPRS-43), the Clinical Global Impressions Scale of Severity (CGI-S), and the Children's Global Assessment Scale. Results: Nine males with a mean age of 3.9 (SD = 1.2) years were treated. The median quetiapine dose at end of study was 150 mg/day (range 75-350). Mean psychometric scores did not change substantively from baseline. No patients experienced extrapyramidal side effects. Three subjects discontinued due to study nonadherence. No patients discontinued treatment due to an adverse event. Conclusions: These preliminary data suggest that quetiapine might be a generally safe and effective maintenance treatment for aggressive children with CD who initially respond to an acute therapeutic trial of quetiapine. More research is needed to confirm or refute these initial findings.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalJournal of Child and Adolescent Psychopharmacology
Volume17
Issue number1
DOIs
StatePublished - Feb 1 2007
Externally publishedYes

Fingerprint

Conduct Disorder
Psychometrics
Outpatients
Child Behavior
Aggression
Therapeutics
Quetiapine Fumarate
Safety
Research

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

A 26-week open-label study of quetiapine in children with conduct disorder. / Findling, Robert L; Reed, Michael D.; O'Riordan, Mary Ann; Demeter, Christine A.; Stansbrey, Robert J.; McNamara, Nora K.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 17, No. 1, 01.02.2007, p. 1-9.

Research output: Contribution to journalArticle

Findling, Robert L ; Reed, Michael D. ; O'Riordan, Mary Ann ; Demeter, Christine A. ; Stansbrey, Robert J. ; McNamara, Nora K. / A 26-week open-label study of quetiapine in children with conduct disorder. In: Journal of Child and Adolescent Psychopharmacology. 2007 ; Vol. 17, No. 1. pp. 1-9.
@article{274a57a60af0457a95d4dd47ba26acf1,
title = "A 26-week open-label study of quetiapine in children with conduct disorder",
abstract = "Objective: The aim of this study was to describe the long-term safety and effectiveness of quetiapine in conduct disorder (CD). Methods: This was an 13-week outpatient follow-up study of an acute trial that enrolled aggressive children ages 6-12 years with a primary diagnosis of CD. To be enrolled into this study, subjects had to have successfully completed participation in the initial 3-week, open-label, outpatient quetiapine trial. Psychometric measures included the Rating of Aggression Against People and/or Property Scale (RAAPP), the Nisonger Child Behavior Rating Form (NCBRF), the Conners' Parent Rating Scale (CPRS-43), the Clinical Global Impressions Scale of Severity (CGI-S), and the Children's Global Assessment Scale. Results: Nine males with a mean age of 3.9 (SD = 1.2) years were treated. The median quetiapine dose at end of study was 150 mg/day (range 75-350). Mean psychometric scores did not change substantively from baseline. No patients experienced extrapyramidal side effects. Three subjects discontinued due to study nonadherence. No patients discontinued treatment due to an adverse event. Conclusions: These preliminary data suggest that quetiapine might be a generally safe and effective maintenance treatment for aggressive children with CD who initially respond to an acute therapeutic trial of quetiapine. More research is needed to confirm or refute these initial findings.",
author = "Findling, {Robert L} and Reed, {Michael D.} and O'Riordan, {Mary Ann} and Demeter, {Christine A.} and Stansbrey, {Robert J.} and McNamara, {Nora K.}",
year = "2007",
month = "2",
day = "1",
doi = "10.1089/cap.2006.0027",
language = "English (US)",
volume = "17",
pages = "1--9",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - A 26-week open-label study of quetiapine in children with conduct disorder

AU - Findling, Robert L

AU - Reed, Michael D.

AU - O'Riordan, Mary Ann

AU - Demeter, Christine A.

AU - Stansbrey, Robert J.

AU - McNamara, Nora K.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Objective: The aim of this study was to describe the long-term safety and effectiveness of quetiapine in conduct disorder (CD). Methods: This was an 13-week outpatient follow-up study of an acute trial that enrolled aggressive children ages 6-12 years with a primary diagnosis of CD. To be enrolled into this study, subjects had to have successfully completed participation in the initial 3-week, open-label, outpatient quetiapine trial. Psychometric measures included the Rating of Aggression Against People and/or Property Scale (RAAPP), the Nisonger Child Behavior Rating Form (NCBRF), the Conners' Parent Rating Scale (CPRS-43), the Clinical Global Impressions Scale of Severity (CGI-S), and the Children's Global Assessment Scale. Results: Nine males with a mean age of 3.9 (SD = 1.2) years were treated. The median quetiapine dose at end of study was 150 mg/day (range 75-350). Mean psychometric scores did not change substantively from baseline. No patients experienced extrapyramidal side effects. Three subjects discontinued due to study nonadherence. No patients discontinued treatment due to an adverse event. Conclusions: These preliminary data suggest that quetiapine might be a generally safe and effective maintenance treatment for aggressive children with CD who initially respond to an acute therapeutic trial of quetiapine. More research is needed to confirm or refute these initial findings.

AB - Objective: The aim of this study was to describe the long-term safety and effectiveness of quetiapine in conduct disorder (CD). Methods: This was an 13-week outpatient follow-up study of an acute trial that enrolled aggressive children ages 6-12 years with a primary diagnosis of CD. To be enrolled into this study, subjects had to have successfully completed participation in the initial 3-week, open-label, outpatient quetiapine trial. Psychometric measures included the Rating of Aggression Against People and/or Property Scale (RAAPP), the Nisonger Child Behavior Rating Form (NCBRF), the Conners' Parent Rating Scale (CPRS-43), the Clinical Global Impressions Scale of Severity (CGI-S), and the Children's Global Assessment Scale. Results: Nine males with a mean age of 3.9 (SD = 1.2) years were treated. The median quetiapine dose at end of study was 150 mg/day (range 75-350). Mean psychometric scores did not change substantively from baseline. No patients experienced extrapyramidal side effects. Three subjects discontinued due to study nonadherence. No patients discontinued treatment due to an adverse event. Conclusions: These preliminary data suggest that quetiapine might be a generally safe and effective maintenance treatment for aggressive children with CD who initially respond to an acute therapeutic trial of quetiapine. More research is needed to confirm or refute these initial findings.

UR - http://www.scopus.com/inward/record.url?scp=33947385020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947385020&partnerID=8YFLogxK

U2 - 10.1089/cap.2006.0027

DO - 10.1089/cap.2006.0027

M3 - Article

C2 - 17343549

AN - SCOPUS:33947385020

VL - 17

SP - 1

EP - 9

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 1

ER -